Companies
8-K ↗8-K ↗
SMMT
Summit Therapeutics Inc.
Summit Therapeutics is a clinical-stage oncology company developing ivonescimab, a bispecific antibody that combines PD-1 blockade with anti-VEGF activity as a single molecule. The company is advancing ivonescimab in Phase III trials for non-small cell lung cancer and colorectal cancer, with its lead HARMONi trial in EGFR-mutated NSCLC demonstrating statistically significant improvement in progression-free survival with a hazard ratio of 0.52 compared to chemotherapy alone, and a positive trend in overall survival.
$21.46-11.03%1Y
SMMT · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Non-Squamous Non-Small Cell Lung Cancer
Phase 3Metastatic Colorectal Cancer (CRC)
Phase 3Metastatic Colorectal Cancer (CRC)
Phase 3Non-Small Cell Lung Cancer
Phase 3Non-Small Cell Lung Cancer
UnknownIndication pending review
Catalyst Calendar
Past (2)
MAY 31
Conf.ivonescimab
“This data is planned to be released at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting during an oral presentation on Friday, May 31, 2024, scheduled for 4:57pm CT.”
MAY 30
Readoutivonescimab
“On May 30, 2025, Summit Therapeutics Inc. (the "Company") announced topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab in combination with chemotherapy.”